TLR7 Promotes Tumor Progression, Chemotherapy Resistance, and Poor Clinical Outcomes in Non–Small Cell Lung Cancer

Activation of an immune stimulatory molecule, TLR7, studied mainly in immune cells but also highly expressed in human lung carcinoma cells, confers powerful tumor growth advantage that may be mediated in part by NF-κB, perhaps helping explain its contributions to cancer.